Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and l-DOPA-Induced Dyskinesia

Full text
Author(s):
Ferreira Junior, Nilson Carlos [1, 2] ; dos-Santos-Pereira, Mauricio [1, 3] ; Guimaraes, Francisco Silveira [1, 2] ; Del Bel, Elaine [1, 2, 3]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo - Brazil
[2] Univ Sao Paulo, FMRP, Dept Pharmacol, Campus USP, Av Bandeirantes 13400, BR-14049900 Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, FORP, Dept Basic & Oral Biol, Campus USP, Av Cafe S-N, BR-14040904 Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Review article
Source: NEUROTOXICITY RESEARCH; OCT 2019.
Web of Science Citations: 0
Abstract

Parkinson's disease (PD) and l-DOPA-induced dyskinesia (LID) are motor disorders with significant impact on the patient's quality of life. Unfortunately, pharmacological treatments that improve these disorders without causing severe side effects are not yet available. Delay in initiating l-DOPA is no longer recommended as LID development is a function of disease duration rather than cumulative l-DOPA exposure. Manipulation of the endocannabinoid system could be a promising therapy to control PD and LID symptoms. In this way, phytocannabinoids and synthetic cannabinoids, such as cannabidiol (CBD), the principal non-psychotomimetic constituent of the Cannabis sativa plant, have received considerable attention in the last decade. In this review, we present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in PD and LID. Here, we discuss CBD pharmacology, as well as its neuroprotective effects and those of other cannabinoids. Finally, we discuss the modulation of several pro- or anti-inflammatory factors as possible mechanisms responsible for the therapeutic/neuroprotective potential of Cannabis-derived/cannabinoid synthetic compounds in motor disorders. (AU)

FAPESP's process: 12/17626-7 - Cellular and molecular mechanisms involved in the role of atypical neurotransmitters in neuropsychiatric disorders
Grantee:Francisco Silveira Guimaraes
Support type: Research Projects - Thematic Grants
FAPESP's process: 14/25029-4 - Contribution of the neuroinflamation to L-DOPA induced dyskinesia
Grantee:Elaine Aparecida Del Bel Belluz Guimarães
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/14207-7 - THE ACTION OF CANNABINOID DRUGS IN L-DOPA-INDUCED DISCINESIA: ANALYSIS OF NEUROINFLAMATION AND GLUTAMATE RELEASE IN GLIAL CELLS
Grantee:Maurício dos Santos Pereira
Support type: Scholarships in Brazil - Post-Doctorate